Tscan Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TCRX Nasdaq 8731 https://www.tscan.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tscan Therapeutics Inc

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors - Jun 6th, 2023 11:00 am
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting - Jun 1st, 2023 8:10 pm
TScan Therapeutics Announces Closing of Public Offering - Jun 1st, 2023 8:05 pm
TScan Therapeutics to Participate in the Jefferies Healthcare Conference - Jun 1st, 2023 11:00 am
TScan Therapeutics Announces Pricing of $140 Million Public Offering - May 26th, 2023 4:37 am
TScan Therapeutics Announces Launch of Proposed Public Offering - May 25th, 2023 8:06 pm
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors - May 24th, 2023 8:13 pm
TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients - May 17th, 2023 8:35 pm
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting - May 17th, 2023 11:00 am
Institutional investors control 30% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 112% - May 11th, 2023 11:33 am
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates - May 10th, 2023 12:15 pm
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 10th, 2023 11:00 am
Why Are TScan Therapeutics Shares Are Shooting Higher Today - May 9th, 2023 5:29 pm
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease - May 9th, 2023 1:00 pm
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting - May 2nd, 2023 8:42 pm
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors - Apr 10th, 2023 11:00 am
TScan Therapeutics Announces CEO Transition - Mar 31st, 2023 12:00 pm
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies - Mar 14th, 2023 11:00 am
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference - Mar 13th, 2023 8:05 pm